Health Affordability Emerges as the Midterms' Defining Macro Variable, Axios-Ipsos Poll Finds
A new Axios-Ipsos survey finds that majorities of Americans are prepared to make health-care affordability a ballot-box priority this November, injecting a sector-specific policy risk into the election cycle that has historically…
HONG KONG— June 28, 2026
A new Axios-Ipsos survey finds that majorities of Americans are prepared to make health-care affordability a ballot-box priority this November, injecting a sector-specific policy risk into the election cycle that has historically repriced insurance and pharmaceutical equities. The poll, conducted June 12-15, 2026 among 1,189 adults with a margin of error of plus or minus 2.9 percentage points, shows cost pressures on gas, groceries, and other basics converging with health-care stress into a unified demand for government relief — a signal with direct read-through to legislative risk for insurers, pharmacy benefit managers, and drug manufacturers.
Affordability Displaces Ideology on the Campaign Trail
About half of respondents told Axios-Ipsos that measures aimed at drug and insurance affordability will likely influence who they vote for in November. More than six in ten said they support direct-to-consumer drug sales — a channel that could compress distributor and pharmacy-benefit-manager margins — and a similar proportion backs reinstating the enhanced Affordable Care Act subsidies that Congress allowed to expire at the end of last year. Mallory Newall, Ipsos vice president for U.S. public affairs, noted that hearing "lowering costs" is sufficient for most Americans to back a policy initiative, even without familiarity with its specifics.
The pattern echoes two prior cycles in which health care proved pivotal: the 2018 and 2022 midterms. What distinguishes 2026 is the convergence with broader cost-of-living strain, making affordability demands self-reinforcing across income groups.
Party Lines Fracture on Subsidies, Hold on Drug Pricing
The poll reveals a sharper partisan divide on ACA subsidy restoration than on drug-pricing reform. Seventy-one percent of Democrats and 49% of independents say they would be more likely to support a candidate who favors reviving enhanced marketplace subsidies; only 26% of Republicans agree. Newall described "subsidies" and "Obamacare" as partisan trigger words — a dynamic that could allow Republicans to run toward the issue rather than away from it.
Drug-discount platforms draw broader cross-aisle support: 54% of all respondents said they'd be likelier to back a candidate who supports expanding platforms such as TrumpRx and GoodRx. That bipartisan coalition gives drug-pricing legislation a viable pathway that subsidy restoration currently lacks.
Demographic Stress and the GLP-1 Knowledge Gap
Price-sensitive cohorts — Americans aged 30 to 49, parents of children under 18, and households earning below $50,000 — are absorbing the sharpest affordability strain. Twenty-six percent of all respondents said they are very or somewhat likely to shop for a new health plan this year owing to rising costs, and 72% expressed concern about premium increases ahead.
A separate finding flags a structural market development: 26% of respondents said they or someone they know used a prescription weight-loss drug in the past three months, up from 18% in March. Yet fewer than a third were aware of research suggesting GLP-1 drugs carry additional benefits — including a potential reduction in Alzheimer's risk — and less than 10% knew about microdosing protocols. Newall described the gap as a "big black box" around medicines that are already reshaping patient behaviour and pharmacy volumes. That asymmetry between surging utilisation and limited public understanding carries its own reimbursement and regulatory risk heading into the vote.
Related reading
Source · 來源